

Glucagon (1-29), bovine, human, porcine

Cat. No.:	HY-P0082		
CAS No.:	16941-32-5		
Molecular Formula:	C ₁₅₃ H ₂₂₅ N ₄₃ O ₄₉ S		
Molecular Weight:	3482.75	HSQGTFTSDYSKYLDSRRRAQDFVQWLMNT	
Sequence:	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr		
Sequence Shortening:	HSQGTFTSDYSKYLDSRRRAQDFVQWLMNT		
Target:	GCGR		
Pathway:	GPCR/G Protein		
Storage:	Sealed storage, away from moisture and light		
	Powder	-80°C	2 years
		-20°C	1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)		

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 6.67 mg/mL (1.92 mM; ultrasonic and adjust pH to 3 with HCl)				
	DMSO : 2 mg/mL (0.57 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent \ Mass \ Concentration	1 mg	5 mg	10 mg
		1 mM	0.2871 mL	1.4356 mL	2.8713 mL
		5 mM	---	---	---
10 mM		---	---	---	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.2 mg/mL (0.06 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 0.2 mg/mL (0.06 mM); Suspended solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis ^[1] . Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation ^{[2][3]} .
In Vitro	Upon binding to its receptor Gcgr, Glucagon activates cAMP-PKA signaling to stimulate hepatic glucose production (HGP)

and cause hyperglycemia^[1].
?Glucagon stimulates both hepatic kisspeptin1 production and gluconeogenesis^[1].
?Glucagon (100 nM) represses CYP7A1 mRNA expression in human primary hepatocytes^[3].
?Glucagon (100 nM) increases phosphorylation of HNF4 α ^[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis^[3]

Cell Line:	Human primary hepatocytes (H1211, HH1215)
Concentration:	100 nM
Incubation Time:	
Result:	Resulted in a marked increase in the amount of phosphorylated HNF4 α .

In Vivo

Low-dose (20 μ g/kg) Glucagon increases glycemia and does not stimulate insulin secretion in ambient-fed mice. High-dose (1 mg/kg) Glucagon lowers glycemia compared with PBS control and stimulates insulin secretion in ambient-fed mice^[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice (12- to 24-week-old) ^[4]
Dosage:	20 μ g/kg and 1 mg/kg
Administration:	Administered by i.p. injection; 45 minutes
Result:	Low-dose (20 μ g/kg) increased glycemia and did not stimulate insulin secretion. High-dose (1 mg/kg) lowered glycemia and stimulated insulin secretion.

CUSTOMER VALIDATION

- Cell Res. 2023 Apr;33(4):273-287.
- Nat Metab. 2022 Jan 6.
- Mol Cell. 2023 Feb 22;S1097-2765(23)00102-8.
- Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3144-3149.
- Phytomedicine. 2021 Mar;83:153487.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Song WJ, et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab. 2014 Apr 1;19(4):667-81.
- [2]. Hirota K, et al. Hepatocyte nuclear factor-4 is a novel downstream target of insulin via FKHR as a signal-regulated transcriptional inhibitor. J Biol Chem. 2003 Apr 11;278(15):13056-60.
- [3]. Song KH, et al. Glucagon and cAMP inhibit cholesterol 7 α -hydroxylase (CYP7A1) gene expression in human hepatocytes: discordant regulation of bile acid synthesis and gluconeogenesis. Hepatology. 2006 Jan;43(1):117-25.
- [4]. Capozzi ME, et al. Glucagon lowers glycemia when β -cells are active. JCI Insight. 2019 Jul 23;5. pii: 129954.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA